A practical reference on electron paramagnetic resonance: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-06 and is reviewed periodically as new material appears.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Long-term storage | -20 °C | Dry powder, sealed and protected from light |
| Working storage | 2 to 8 °C | Short-term holding; avoid repeated warming cycles |
| Purity assay | Reversed-phase HPLC with UV detection | Detection commonly near 214 nm |
| Copper assay | ICP-OES or atomic absorption | Confirms metal content and the metal-to-peptide ratio |
| Visible absorption | Roughly 520 to 600 nm | Rapid indicator of complex integrity |
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
=== Cited texts === Borror DJ, Triplehorn CA, Delong DM (1989). Introduction to the Study of Insects (6th ed.). Saunders College Publishing. ISBN 978-0-03-025397-3. Hölldobler B, Wilson EO (1990). The Ants. Harvard University Press. ISBN 978-0-674-04075-5.
In the cell membrane peptides fold into helices and sheets to allow the non-polar residues to interact with the membrane interior, and to allow the polar residues to be exposed to the aqueous environment. This self-assembly allows the peptides to further optimise their interaction with the surroundings. Peptide amphiphiles are very useful in biomedical applications, and can be utilised to act as therapeutic agents to treat diseases by transporting drugs across membranes to specific sites. They can then be metabolised into lipids and amino acids, which are then easily removed in the kidneys. This occurs by the hydrophobic tail being able to cross the cell membrane, allowing the peptide epitope to target a specific cell by a ligand- receptor complex. Other applications of peptide amphiphiles are use in antimicrobials, skincare and cosmetics, and also gene delivery to name a few.
=== Genetically engineered biofactories === Various yeast species have been genetically engineered to efficiently produce various drugs, a technique called metabolic engineering. S. cerevisiae is easy to genetically engineer; its physiology, metabolism and genetics are well known, and it is amenable for use in harsh industrial conditions. A wide variety of chemical in different classes can be produced by engineered yeast, including phenolics, isoprenoids, alkaloids, and polyketides. About 20% of biopharmaceuticals are produced in S. cerevisiae, including insulin, vaccines for hepatitis, and human serum albumin.
=== Independent bottlers === Most malt distilleries sell a significant amount of whisky by the cask for blending, and sometimes to private buyers as well. Whisky from such casks is sometimes bottled as a single malt by independent bottling firms such as Duncan Taylor, Master of Malt, Gordon & MacPhail, Cadenhead's, The Scotch Malt Whisky Society, Murray McDavid, Berry Bros. & Rudd, Douglas Laing, Adelphi and others. These are usually labelled with the distillery's name, but not using the distillery's trademarked logos or typefaces. An "official bottling" (or "proprietary bottling"), by comparison, is from the distillery (or its owner). Many independent bottlings are from single casks, and they may sometimes be very different from an official bottling. For a variety of reasons, some independent bottlers do not identify which distillery produced the whisky in the bottle. Mostly this will be at the request of the whisky distiller as they are unable to regulate the quality of the whisky sold. Some distilleries, to prevent third-party bottlers from naming them on the bottle, add a small amount of whisky from a different distillery, a technique called 'tea-spooning' which then precludes the sale of the whisky as from a specific distillery, or as a single malt; the addition of any whisky from a second distillery is by regulation a blended malt (which will also allow it to be exported in bulk form, unlike single malts which may only be exported bottled ready for sale).
Sources: en.wikipedia.org
==== Above-ground disposal ==== Dry cask storage typically involves taking waste from a spent fuel pool and sealing it (along with an inert gas) in a steel cylinder, which is placed in a concrete cylinder which acts as a radiation shield. It is a relatively inexpensive method which can be done at a central facility or adjacent to the source reactor. The waste can be easily retrieved for reprocessing.
Regular insulin, also known as neutral insulin and soluble insulin, is a type of short-acting medical insulin. It is used to treat type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Typically it is given by injection under the skin, but may also be used by injection into a vein or muscle. Onset of effect is typically in 30 minutes and it typically lasts for 8 hours. The common side effect is low blood sugar. Other side effects may include pain or skin changes at the sites of injection, low blood potassium, and allergic reactions. Use during pregnancy is relatively safe for the baby. Regular insulin can be made from the pancreas of pigs or cows. Human versions can be made either by modifying pig versions or recombinant technology. Insulin was first used as a medication in Canada by Charles Best and Frederick Banting in 1922. It is on the World Health Organization's List of Essential Medicines. In 2017, it was the 209th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Versions are also available mixed with longer-acting versions of insulin, such as NPH insulin. In 2020, the combination of human insulin with insulin isophane was the 246th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Pepsin is one of the primary causes of mucosal damage during laryngopharyngeal reflux. Pepsin remains in the larynx (pH 6.8) following a gastric reflux event. While enzymatically inactive in this environment, pepsin would remain stable and could be reactivated upon subsequent acid reflux events. Exposure of laryngeal mucosa to enzymatically active pepsin, but not irreversibly inactivated pepsin or acid, results in reduced expression of protective proteins and thereby increases laryngeal susceptibility to damage. Pepsin may also cause mucosal damage during weakly acidic or non-acid gastric reflux. Weak or non-acid reflux is correlated with reflux symptoms and mucosal injury. Under non-acid conditions (neutral pH), pepsin is internalized by cells of the upper airways such as the larynx and hypopharynx by a process known as receptor-mediated endocytosis. The receptor by which pepsin is endocytosed is currently unknown. Upon cellular uptake, pepsin is stored in intracellular vesicles of low pH at which its enzymatic activity would be restored. Pepsin is retained within the cell for up to 24 hours. Such exposure to pepsin at neutral pH and endocyctosis of pepsin causes changes in gene expression associated with inflammation, which underlies signs and symptoms of reflux, and tumor progression. This and other research implicates pepsin in carcinogenesis attributed to gastric reflux. Pepsin in airway specimens is considered to be a sensitive and specific marker for laryngopharyngeal reflux.
Sources: en.wikipedia.org
In the DEA's "National Drug Threat Assessment 2024", director Milgram outlined the "most dangerous and deadly crisis", involving synthetic drugs including fentanyl and methamphetamine. She singled out the Sinaloa and Jalisco cartels in Mexico, which manufacture the synthetics in Mexican labs supplied with precursor chemicals and machinery from China, sell through "vast distribution networks" in the US, and use Chinese money laundering operations to return the proceeds to Mexico. Milgram states, "As the lead law enforcement agency in the Administration's whole-of-government response to defeat the Cartels and combat the drug poisoning epidemic in our communities, DEA will continue to collaborate on strategic counterdrug initiatives with our law enforcement partners across the United States and the world."
== History == During the 1980s, Jean-Pierre Raufman worked as a postdoctoral researcher at the National Institutes of Health for John Pisano, a biochemist who specialized in collecting venom from various animals and looking for novel substances that could affect human physiology. In the course of this work, Raufman focused on the Gila monster, because he was curious about its practice of eating once or twice per year. He reported that Gila monster venom had biologically active molecules that provoked inflammation of the pancreas in test animals. In 1992, after learning of Raufman's findings, John Eng of the Veterans Administration Medical Center in New York City used radioimmunoassay to isolate a novel substance from Gila monster venom. The new substance, which Eng called exendin-4, was similar to GLP-1 in that it reduced blood glucose in diabetic mice, but exendin-4 had a much longer half-life than GLP-1, whose extremely short half-life had defeated earlier attempts to turn it into a drug. Eng filed a patent application for exendin-4 in 1993. He then spent three years searching for a pharmaceutical industry partner interested in commercializing exendin-4. In 1996, Amylin Pharmaceuticals licensed Eng's patent and created a synthetic version of exendin-4 called exenatide. In 2002, Eli Lilly and Company partnered with Amylin to develop exenatide and secure approval to market the drug. Exenatide's 2005 approval by the U.S.
Carfentanil or carfentanyl, formerly sold under the brand name Wildnil, is an extremely potent opioid analgesic formerly used in veterinary medicine to anesthetize large animals such as elephants and rhinoceroses. It is a structural analogue of the synthetic opioid analgesic fentanyl. It is typically administered in this context by tranquilizer dart. Carfentanil has also been used in humans to image opioid receptors. It has additionally been used as a recreational drug, typically by injection, insufflation, or inhalation. Deaths have been reported in association with carfentanil. Effects and side effects of carfentanil in humans are similar to those of other opioids and include euphoria, relaxation, pain relief, pupil constriction, drowsiness, sedation, slowed heart rate, low blood pressure, lowered body temperature, loss of consciousness, and suppression of breathing. The effects of carfentanil, including overdose, can be reversed by the opioid antagonists naloxone and naltrexone, though higher doses than usual may be necessary compared to other opioids. It acts as an ultrapotent and highly selective agonist of the μ-opioid receptor. Carfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceuticals which included Paul Janssen. It was introduced into veterinary medicine in 1986. Carfentanil is legally controlled in most jurisdictions.
Sources: en.wikipedia.org
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.
The colour comes from electronic transitions between the copper ion and the surrounding peptide nitrogen atoms. The resulting absorption sits in the visible region, giving the solid and its solutions a blue to violet appearance. Loss of colour can indicate that the copper has dissociated from the peptide.
Chromatography establishes the identity and purity of the peptide, while elemental analysis establishes the copper content. The two results should agree with a one-to-one ratio. Visible spectroscopy adds a quick check that the complex itself is intact.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.